30 Day Trial

New Evidence-Based Recommendation for Lateral Interbody Fusion in UK

Share:

NuVasive (NUVA) announced updated guidance from NICE, the National Industry for Clinical Excellence in the U.K., for lateral lumbar interbody fusion.

NICE stated that current evidence on the safety of lateral (including extreme, extra and direct lateral) interbody fusion in the lumbar spine for low back pain shows that there are serious but well-known complications.

The organization further stated that evidence on efficacy is adequate in quality and quantity, and the procedure may be used so long as standard arrangements are in place for clinical governance, consent and audit.

The majority of the evidence reviewed by the panel derived from peer-reviewed articles describing 14 years of experience with and outcomes following NUVA's eXtreme Lateral Interbody Fusion (XLIF®) procedure. The updated guidance was supported by a systematic literature review of >200 previously-published studies. 

XLIF has been used in >150,000 surgeries globally since its introduction in 2003, in the U.S. Initial NICE guidance for lateral interbody fusion was published in 2009.

Information on the guidance is available at NICE.org.

Source: NuVasive, Inc.